AgeX Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | SER | US00848H1086 | A2N8PC

날짜	AgeX Therapeutics 주식 가격
	6.71 undefined
	7.44 undefined
	7.49 undefined
	7.50 undefined
	8.63 undefined
	6.62 undefined
	5.96 undefined
	6.01 undefined
	6.06 undefined
	6.34 undefined
	6.44 undefined
	6.18 undefined
	6.75 undefined
	6.85 undefined
	7.40 undefined
	7.97 undefined
	7.95 undefined
	7.89 undefined
	7.98 undefined

날짜	AgeX Therapeutics 매출	AgeX Therapeutics EBIT	AgeX Therapeutics 이익
2023	142,000 undefined	-9.96 백만 undefined	-14.8 백만 undefined
2022	30,000 undefined	-6.98 백만 undefined	-10.46 백만 undefined
2021	140,000 undefined	-8.04 백만 undefined	-8.68 백만 undefined
2020	360,000 undefined	-10.1 백만 undefined	-10.87 백만 undefined
2019	1.73 백만 undefined	-12.56 백만 undefined	-12.15 백만 undefined
2018	1.4 백만 undefined	-11.25 백만 undefined	-7.5 백만 undefined
2017	1.4 백만 undefined	-8.41 백만 undefined	-6.58 백만 undefined
2016	1.67 백만 undefined	-12.74 백만 undefined	-15.49 백만 undefined

	매출	EBIT	이익
2016	1.67 백만 USD	-12.74 백만 USD	-15.49 백만 USD
2017	1.4 백만 USD	-8.41 백만 USD	-6.58 백만 USD
2018	1.4 백만 USD	-11.25 백만 USD	-7.5 백만 USD
2019	1.73 백만 USD	-12.56 백만 USD	-12.15 백만 USD
2020	360,000 USD	-10.1 백만 USD	-10.87 백만 USD
2021	140,000 USD	-8.04 백만 USD	-8.68 백만 USD
2022	30,000 USD	-6.98 백만 USD	-10.46 백만 USD
2023	142,000 USD	-9.96 백만 USD	-14.8 백만 USD

2016	2017	2018	2019	2020	2021	2022	2023
1,000	1,000	1,000	1,000	0	0	0	0
-	-	-	-	-	-	-	-
100.00	100.00	100.00	100.00	-	-	-	-
1,000	1,000	1,000	1,000	0	0	0	0
-12	-8	-11	-12	-10	-8	-6	-9
-1,200.00	-800.00	-1,100.00	-1,200.00	-	-	-	-
-15	-6	-7	-12	-10	-8	-10	-14
-	-60.00	16.67	71.43	-16.67	-20.00	25.00	40.00
35.83	35.83	34.91	37.27	37.67	37.89	37.95	1.08
-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022	2023

0.26	7.38	6.71	2.35	0.53	0.58	0.65	0.35
310	110	130	360	330	30	0	57
0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0
0.12	0.11	1.02	1.34	1.43	1.63	1.8	0.35
0.69	7.6	7.86	4.05	2.29	2.24	2.45	0.75
0.2	0.13	0.09	1.13	0	0	0	0
0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	10.55
2.3	1.87	2.71	2.15	1.59	0.87	0.74	0.61
0	0	0	0	0	0	0	0
40	40	20	110	50	50	50	50
2.54	2.04	2.82	3.39	1.64	0.92	0.79	11.21
3.23	9.64	10.68	7.44	3.93	3.16	3.24	11.97

0	0	0	0	0	0	0	0
36.49	73.76	81.5	88.35	91.81	93.91	98.99	136.48
-59.97	-66.55	-74.05	-86.21	-97.07	-105.75	-116.21	-131.01
60	70	0	70	140	0	0	-0.01
0	0	0	0	0	0	0	0
-23.42	7.28	7.45	2.21	-5.12	-11.84	-17.22	5.47
0.26	0.08	0.15	0.42	0.76	0.19	0.57	1.41
1.83	0.69	1.27	1.59	0.9	0.58	0.47	0.76
23.51	0.54	1.02	1.29	1.31	1.06	1.4	0.07
0	0	0	0	440	0	0	0
0	0	0	0	1.96	7.14	7.65	3.67
25.6	1.31	2.44	3.3	5.37	8.97	10.09	5.91
0	0	0	1.53	3.9	6.06	10.48	0.69
0	0	0	0	0	0	0	0
0	0	0	0	60	0	0	0
0	0	0	1.53	3.96	6.06	10.48	0.69
25.6	1.31	2.44	4.83	9.33	15.03	20.57	6.61
2.18	8.59	9.89	7.04	4.21	3.19	3.35	12.08

2016	2017	2018	2019	2020	2021	2022	2023
-15	-6	-7	-12	-10	-8	-10	-14
0	0	0	0	1,000	0	0	0
0	0	0	0	0	0	0	0
1,000	0	0	0	0	0	0	1,000
4	-1	-1	1	1	1	4	5
0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0
-8	-6	-8	-10	-7	-7	-5	-7
0	0	-1	0	0	0	0	0
0	0	1,000	0	0	0	0	-10,000
0	0	3	0	0	0	0	-10
0	0	0	0	0	0	0	0
7	3	0	1	6	7	6	17
0	10	6	4	0	0	0	0
7	13	6	6	5	7	6	17
-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0
-1	7	0	-4	-1	0	0	0
-8.45	-6.29	-9.89	-10.8	-7.84	-7.86	-5.94	-7.8
0	0	0	0	0	0	0	0

AgeX Therapeutics 브루토마진	AgeX Therapeutics 이익 마진	AgeX Therapeutics EBIT-마진	AgeX Therapeutics 이익 마진
2023	71.83 %	-7,014.09 %	-10,424.65 %
2022	66.67 %	-23,266.67 %	-34,866.67 %
2021	92.86 %	-5,742.86 %	-6,200 %
2020	94.44 %	-2,805.56 %	-3,019.44 %
2019	85.55 %	-726.01 %	-702.31 %
2018	73.57 %	-803.57 %	-535.71 %
2017	88.57 %	-600.71 %	-470 %
2016	81.44 %	-762.87 %	-927.54 %

	브루토마진	EBIT-마진	이익 마진
2016	81.44 %	-762.87 %	-927.54 %
2017	88.57 %	-600.71 %	-470 %
2018	73.57 %	-803.57 %	-535.71 %
2019	85.55 %	-726.01 %	-702.31 %
2020	94.44 %	-2,805.56 %	-3,019.44 %
2021	92.86 %	-5,742.86 %	-6,200 %
2022	66.67 %	-23,266.67 %	-34,866.67 %
2023	71.83 %	-7,014.09 %	-10,424.65 %

날짜	AgeX Therapeutics 주당 매출	AgeX Therapeutics EBIT 당 주식	AgeX Therapeutics 주당 이익
2023	0.13 undefined	-9.23 undefined	-13.72 undefined
2022	0 undefined	-0.18 undefined	-0.28 undefined
2021	0 undefined	-0.21 undefined	-0.23 undefined
2020	0.01 undefined	-0.27 undefined	-0.29 undefined
2019	0.05 undefined	-0.34 undefined	-0.33 undefined
2018	0.04 undefined	-0.32 undefined	-0.21 undefined
2017	0.04 undefined	-0.23 undefined	-0.18 undefined
2016	0.05 undefined	-0.36 undefined	-0.43 undefined

	주당 매출	EBIT 당 주식	주당 이익
2016	0.05 USD	-0.36 USD	-0.43 USD
2017	0.04 USD	-0.23 USD	-0.18 USD
2018	0.04 USD	-0.32 USD	-0.21 USD
2019	0.05 USD	-0.34 USD	-0.33 USD
2020	0.01 USD	-0.27 USD	-0.29 USD
2021	0 USD	-0.21 USD	-0.23 USD
2022	0 USD	-0.18 USD	-0.28 USD
2023	0.13 USD	-9.23 USD	-13.72 USD

	주식 수량
2016	35.83 백만 Aktien
2017	35.83 백만 Aktien
2018	34.91 백만 Aktien
2019	37.27 백만 Aktien
2020	37.67 백만 Aktien
2021	37.89 백만 Aktien
2022	37.95 백만 Aktien
2023	1.08 백만 Aktien

날짜	EPS-예상치	EPS-실제	보고 분기
	0	-0.14 (0 %)	2023 Q3

%-지분	이름	주식	변경
21.27616 %	Juvenescence Ltd	1,889,323	0
0.95967 %	Broadwood Capital, Inc.	85,219	0
0.66002 %	Viegas (Tacey Ph.D.)	58,610	58,610
0.22470 %	The Vanguard Group, Inc.	19,953	95
0.09171 %	Sigma Planning Corporation	8,144	2,987
0.05929 %	Prescott General Partners LLC	5,265	0
0.04635 %	Bridgeway Capital Management, LLC	4,116	0
0.04515 %	Geode Capital Management, L.L.C.	4,009	0
0.03980 %	BlackRock Institutional Trust Company, N.A.	3,534	-218
0.03118 %	Strategic Wealth Investment Group, LLC	2,769	136
0.02264 %	Creative Planning, Inc.	2,010	-6
0.01008 %	Northern Trust Investments, Inc.	895	0
0.00919 %	Virtu Americas LLC	816	816
0.00858 %	State Street Global Advisors (US)	762	0
0.00796 %	Susquehanna International Group, LLP	707	17
0.00721 %	Summit Wealth Strategies	640	-412
0.00687 %	Citadel Advisors LLC	610	610
0.00577 %	Beirne Wealth Consulting Services, LLC	512	0
0.00394 %	LPL Financial LLC	350	0
0.00369 %	Jane Street Capital, L.L.C.	328	328
0.00343 %	Tower Research Capital LLC	305	-70
0.00202 %	Bradsher (Neal C)	179	0
0.00106 %	Mintz (Steven Michael)	94	-3,213
0.00104 %	Osaic Holdings, Inc.	92	-4
0.00065 %	J.P. Morgan Securities LLC	58	0
0.00038 %	West (Michael D)	34	-1,160
0.00032 %	Corsicana & Co	28	0
0.00030 %	Riggs Asset Management Company Inc.	27	-3
0.00020 %	UBS Financial Services, Inc.	18	11
0.00016 %	Advisory Services Network, LLC	14	14
0.00015 %	Morgan Stanley Smith Barney LLC	13	0
0.00010 %	Wells Fargo Advisors	9	-1
0.00009 %	Albion Financial Group	8	-1
0.00006 %	Wells Fargo Bank, N.A.	5	1
0.00006 %	Lindbrook Capital, LLC	5	0
0.00005 %	Verus Investors, LLC	4	-265
0.00002 %	Northern Trust Global Investments	2	0
0.00002 %	BNP Paribas Securities Corp. North America	2	0
0.00001 %	Avior Wealth Management, LLC	1	0
0.00001 %	BofA Global Research (US)	1	1
0 %	Piscataqua Savings Bank	0	-28
0 %	GWM Advisors LLC	0	0
0 %	Capital Advisors, Ltd., LLC	0	-1
0 %	Carson Wealth Management Group	0	-6
0 %	Pacifica Partners Inc.	0	-8
0 %	RBC Dominion Securities, Inc.	0	-1
0 %	Two Sigma Investments, LP	0	-309
0 %	The Trust Company of Vermont	0	-3
0 %	Millennium Management LLC	0	-492
0 %	BlackRock Investment Management, LLC	0	-11
0 %	Planning Capital Management Corp	0	0
0 %	Park (Andrea Eun Jae)	0	-10

What values and corporate philosophy does AgeX Therapeutics represent?

AgeX Therapeutics Inc represents innovation, scientific excellence, and a patient-centered approach in the field of regenerative medicine. The company is committed to developing and commercializing breakthrough technologies that target the underlying causes of aging-related diseases. AgeX Therapeutics Inc believes in the power of stem cells and focuses on advancing the potential of induced pluripotent stem cells (iPSCs) to rejuvenate and repair damaged tissues. With a strong emphasis on research and collaboration, AgeX Therapeutics Inc aims to transform the way age-related conditions are treated, ultimately improving the quality of life for patients.

In which countries and regions is AgeX Therapeutics primarily present?

AgeX Therapeutics Inc is primarily present in the United States.

What significant milestones has the company AgeX Therapeutics achieved?

AgeX Therapeutics Inc. has achieved several significant milestones since its inception. Firstly, the company successfully developed its proprietary PureStem® and UniverCyte™ technology platforms, which serve as a foundation for the development of regenerative medicine products. They also established the AgeX Bioengineering Division to advance the life extension and rejuvenation technology. Additionally, AgeX formed a subsidiary, LifeBio, focused on using artificial intelligence and big data analytics to extend human health span. Furthermore, AgeX Therapeutics made strategic collaborations and partnerships, including a licensing agreement with Lineage Cell Therapeutics for the development and commercialization of OpRegen®, a retinal pigment epithelium transplant therapy. These achievements highlight the company's dedication to advancing regenerative medicine and positioning itself as a leader in the field.

What is the history and background of the company AgeX Therapeutics?

AgeX Therapeutics Inc is a life sciences company focused on developing and commercializing innovative technologies to reverse the effects of aging. Founded in 2017, AgeX is a subsidiary of BioTime Inc., with headquarters in Alameda, California. The company is dedicated to leveraging breakthroughs in the field of regenerative medicine to address the challenges posed by age-related diseases. AgeX Therapeutics Inc's research and development efforts primarily revolve around the identification and utilization of pluripotent stem cells, tissue engineering, and bioengineering technologies. By utilizing these advanced approaches, AgeX aims to improve human health and extend the healthy lifespan.

Who are the main competitors of AgeX Therapeutics in the market?

Some of the main competitors of AgeX Therapeutics Inc in the market are companies like BioTime Inc and Lineage Cell Therapeutics Inc.

In which industries is AgeX Therapeutics primarily active?

AgeX Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of AgeX Therapeutics?

The business model of AgeX Therapeutics Inc is focused on the development and commercialization of innovative therapies for the aging process and age-related diseases. By leveraging their proprietary technologies and research expertise, AgeX aims to address the underlying causes of aging and enhance human healthspan. The company is dedicated to identifying and targeting specific biological mechanisms that contribute to age-related decline, with the potential to extend healthy lifespans. AgeX Therapeutics Inc combines regenerative medicine, cell therapy, and genetic engineering to explore groundbreaking solutions for age-related diseases such as osteoarthritis. Their comprehensive approach positions AgeX as a leading player in the field of longevity and rejuvenation research.

AgeX Therapeutics 2024의 P/E 비율은 얼마입니까?

AgeX Therapeutics에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

AgeX Therapeutics 2024의 KUV는 얼마입니까?

AgeX Therapeutics에 대한 현재 KUV는 계산할 수 없습니다.

AgeX Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

AgeX Therapeutics에 대한 AlleAktien 품질 점수는 1/10입니다.

AgeX Therapeutics 2024의 매출은 얼마인가요?

AgeX Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

AgeX Therapeutics 2024의 이익은 얼마인가요?

AgeX Therapeutics의 현재 이익을 계산할 수 없습니다.

AgeX Therapeutics은 무엇을 하나요?

AgeX Therapeutics Inc is a US-based company specializing in the development of therapeutic agents for rejuvenation and regeneration of tissues and organs. The company was founded in 2017 and is headquartered in Alameda, California. The business model of AgeX Therapeutics is based on the discovery and development of new technologies and therapeutic approaches to improve the health and quality of life of people. The company focuses on the research of stem cells and their ability to regenerate tissues and organs. AgeX Therapeutics is divided into several business segments, each focusing on specific therapeutic approaches. One of these business segments is the production of cell lines that have undergone paramyxovirus-based de-differentiation to generate pluripotent cells. These cells can be used to manufacture replacement tissues and organs to treat patients with chronic diseases such as diabetes, heart disease, or liver disease. Another business segment is the development of hydrogel-based technologies to enhance stem cell therapy. These technologies aim to accelerate tissue and organ regeneration and improve the effectiveness of stem cell therapies. AgeX Therapeutics also offers products and services in the field of diagnostics and insurance. The company has partnered with Juvenescence Ltd., a company in the field of aging research, to develop and introduce cancer diagnostic tests based on epigenetic markers. These tests aim to enable doctors to detect cancer at an early stage and initiate appropriate treatments. In addition, AgeX Therapeutics also offers services in the field of aging insurance. The company has partnered with Insilico Medicine, Inc. to develop machine learning technologies for identifying biological aging markers. These technologies aim to shape insurance rates based on individual biological age. AgeX Therapeutics has acquired a variety of patents and intellectual property, including the exclusive right to use GDF-11 technology for the treatment of aging processes. The company has also partnered with Lineage Cell Therapeutics, Inc. to advance the development of replacement tissues and organs based on pluripotent cells. In summary, AgeX Therapeutics' business model is based on the discovery and development of technologies for rejuvenation and regeneration of tissues and organs. The company focuses on the research of stem cells and their ability to regenerate tissues and organs. AgeX Therapeutics is divided into several business segments, each focusing on specific therapeutic approaches, and also offers products and services in the field of diagnostics and insurance. With its expertise in stem cells and regeneration, AgeX Therapeutics has the potential to play a leading role in the aging industry.

AgeX Therapeutics 배당금은 얼마입니까?

AgeX Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

AgeX Therapeutics이 얼마나 자주 배당을 지급하나요?

AgeX Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

AgeX Therapeutics ISIN이 무엇입니까?

AgeX Therapeutics의 ISIN은 US00848H1086입니다.

AgeX Therapeutics WKN은 무엇인가요?

AgeX Therapeutics의 WKN은 A2N8PC입니다.

AgeX Therapeutics 티커는 무엇인가요?

AgeX Therapeutics의 티커는 SER입니다.

AgeX Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 AgeX Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 AgeX Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

AgeX Therapeutics의 배당 수익률은 얼마입니까?

AgeX Therapeutics의 현재 배당 수익률은 입니다.

AgeX Therapeutics의 배당금은 언제 지급되나요?

AgeX Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

AgeX Therapeutics의 배당금은 얼마나 안전한가요?

AgeX Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

AgeX Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

AgeX Therapeutics이(가) 속해 있는 섹터는 어디인가요?

AgeX Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von AgeX Therapeutics kaufen, um die vorherige Dividende zu erhalten?

AgeX Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

AgeX Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

AgeX Therapeutics의 2023년도 배당금은 얼마였습니까?

2023년에 AgeX Therapeutics는 0 USD를 배당금으로 지급했습니다.

AgeX Therapeutics는 어떤 화폐로 배당금을 지급하나요?

AgeX Therapeutics의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	—
스코프 2 - 구매한 에너지로부터의 간접적인 배출	—
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	—
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	✅
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	—
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	❌
개인정보 보호 정책	—
작업 및 건강 보호	❌
카톨릭	✅

환경 보고	❌
이해관계자 참여	❌
콜백 정책	❌
카르텔법	❌

증권거래소	AgeX Therapeutics 티커
AMEX	AGE
프랑크푸르트	0X4.F
뮌헨	0X4.MU

AgeX Therapeutics 티커	AgeX Therapeutics FIGI
AGE:US	BBG00HCXQ7B0
AGE:UA	BBG00L4GS486
AGE:UC	BBG00L4GS495
AGE:UN	BBG00L4GS4C1
AGE:UP	BBG00L4GS4D0
AGE:UB	BBG00L4GS4G7
AGE:UT	BBG00L4GS4H6
AGE:UM	BBG00L4GS4J4
AGE:UX	BBG00L4GS4K2
AGE:UD	BBG00L4GS4Q6
AGE:UF	BBG00L4GS4T3
AGE:VY	BBG00L4GS4V0
AGE:VJ	BBG00L4GS4W9
AGE:VK	BBG00L4GS4X8
AGE:VF	BBG00L4GS4Y7
0X4:GR	BBG00P2FHKM1
0X4:GF	BBG00P2FHKN0
0X4:GS	BBG00P2FHKR6
0X4:GM	BBG00P2FHKS5
0X4:GB	BBG00P2FHKT4
AGEEUR:XS	BBG00P2VZ2M6
AGEEUR:XH	BBG00P2VZ2Q2
AGEEUR:XF	BBG00P2VZ2S0
AGEEUR:XE	BBG00P2VZ2V6
AGEEUR:XJ	BBG00P2VZ2W5
AGEEUR:XL	BBG00P2VZ2X4
AGEEUR:XG	BBG00P2VZ2Y3
AGEEUR:XO	BBG00P2VZ2Z2
AGEEUR:XA	BBG00P2VZ335
AGEEUR:E1	BBG00P2VZ344
AGEEUR:XT	BBG00P2VZ353
AGEEUR:XW	BBG00P2VZ362
AGEEUR:XU	BBG00P2VZ371
AGEEUR:XV	BBG00P2VZ380
AGEEUR:XM	BBG00P2VZ399
AGEEUR:XQ	BBG00P2VZ3B6
AGEEUR:XX	BBG00P2VZ3C5
AGEEUR:XZ	BBG00P2VZ3D4
AGEEUR:EU	BBG00P2VZ3G1
AGEGBP:XS	BBG00P31XKP0
AGEGBP:XH	BBG00P31XKS7
AGEGBP:XF	BBG00P31XKV3
AGEGBP:XE	BBG00P31XKX1
AGEGBP:XJ	BBG00P31XKY0
AGEGBP:XL	BBG00P31XKZ9
AGEGBP:XG	BBG00P31XL05
AGEGBP:XO	BBG00P31XL14
AGEGBP:XA	BBG00P31XL50
AGEGBP:E1	BBG00P31XL69
AGEGBP:XT	BBG00P31XL78
AGEGBP:XW	BBG00P31XL87
AGEGBP:XU	BBG00P31XL96
AGEGBP:XV	BBG00P31XLB3
AGEGBP:XM	BBG00P31XLC2
AGEGBP:XQ	BBG00P31XLD1
AGEGBP:XX	BBG00P31XLF9
AGEGBP:XZ	BBG00P31XLG8
AGEGBP:EU	BBG00P31XLK3
AGEUSD:XS	BBG00P84G6R7
AGEUSD:XH	BBG00P84G6V2
AGEUSD:XF	BBG00P84G6X0
AGEUSD:XE	BBG00P84G6Z8
AGEUSD:XJ	BBG00P84G704
AGEUSD:XL	BBG00P84G713
AGEUSD:XG	BBG00P84G722
AGEUSD:XO	BBG00P84G731
AGEUSD:XA	BBG00P84G777
AGEUSD:E1	BBG00P84G786
AGEUSD:XT	BBG00P84G795
AGEUSD:XW	BBG00P84G7B2
AGEUSD:XU	BBG00P84G7C1
AGEUSD:XV	BBG00P84G7D0
AGEUSD:XM	BBG00P84G7F8
AGEUSD:XQ	BBG00P84G7G7
AGEUSD:XX	BBG00P84G7H6
AGEUSD:XZ	BBG00P84G7J4
AGEUSD:EU	BBG00P84G7L1
AGEUSD:EP	BBG00QJDLN63
AGEUSD:EZ	BBG00QJDLN81
AGE:VG	BBG00X1PDRR7
AGE:VP	BBG00X1SV544
0X4:TH	BBG00XTH4F28
0X4:GZ	BBG014LR5N92
0X4:LA	BBG018H9RBX3
0X4:LU	BBG018J3DWP2

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커SER

ISINUS00848H1086

WKNA2N8PC

AgeX Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

AgeX Therapeutics 주가 이력

AgeX Therapeutics 주식 매출, EBIT, 이익 US00848H1086 · A2N8PC

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

AgeX Therapeutics 매출, 이익 및 EBIT 역사

AgeX Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

AgeX Therapeutics 주식 마진 US00848H1086 · A2N8PC

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

AgeX Therapeutics 마진 역사

AgeX Therapeutics 주식 매출, EBIT, 주당 순이익 US00848H1086 · A2N8PC

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

AgeX Therapeutics 매출, 이익 및 EBIT 주당 역사

AgeX Therapeutics 주식 및 주식 분석

AgeX Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

AgeX Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

AgeX Therapeutics 주식 수량 US00848H1086 · A2N8PC

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

AgeX Therapeutics 수익 예상

AgeX Therapeutics 수익 놀라움

Eulerpool ESG Scorecard© AgeX Therapeutics 주식을 위해

Eulerpool World ESG Rating (EESG©)

24/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

AgeX Therapeutics 주식 주주 구조

AgeX Therapeutics 임원진 및 경영진

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
SER

ISIN
US00848H1086

WKN
A2N8PC